Prevention of ovarian cancer by administration of progestin products

• US 6,977,250 B2
• Filed: 09/17/2001
• Issued: 12/20/2005
• Est. Priority Date: 09/13/1996
• Status: Expired due to Fees

• Current Assignee: New Life Pharmaceuticals Incorporated
• Original Assignee: New Life Pharmaceuticals Incorporated
• Inventors: Rodriguez, Gustavo C.
• Primary Examiner(s): Kross, Frederick
• Assistant Examiner(s): LEWIS, AMY A
• Application Number:
  US09/954,082
• Publication Number:
  US 20020028795A1
• Time in Patent Office: 1,555 Days
• Field of Search: 514/171, 514/170, 514/177, 514/179, 514/841, 514/843, 514/873, 514/874
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3

Abstract

The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.

Claims

1. A pharmaceutical composition comprising an estrogen product selected from the group consisting of ethinyl estradiol, mestranol, conjugated equine estrogen, estrone, estradiol, esterified estrogens, and estropipate, and a progestin product selected from the group consisting of progesterone, pregnanes, estranes, and gonanes, wherein the ratio of dosages of the progestin product to the estrogen product is greater than 239:

1 by weight in norethindrone/ethinyl estradiol equivalent doses.

2. The composition of claim 1 wherein said progestin product is levonorgestrel.

3. The composition of claim 1 wherein said progestin product is norethindrone.

4. The composition of claim 1 wherein said progestin product is norethynodrel.

5. The composition of claim 1 wherein said progestin product is lynestrenol.

6. The composition of claim 1 wherein said progestin product is norethindrone acetate.

7. The composition of claim 1 wherein said progestin product is ethynodiol acetate.

8. The composition of claim 1 wherein said progestin product is norethindrone enanthate.

9. The composition of claim 1 wherein said progestin product is medroxyprogesterone acetate.

10. The composition of claim 1 wherein said progestin product is chlormadinone acetate.

11. The composition of claim 1 wherein said progestin product is megestrol acetate.

12. The composition of claim 1 wherein said progestin product is cyproterone acetate.

13. The composition of claim 1 wherein said progestin product is norgestrel.

14. The composition of claim 1 wherein said progestin product is norgestimate.

15. The composition of claim 1 wherein said progestin product is desogestrel.

16. The composition of claim 1 wherein said progestin product is gestodene.